Abbott Laboratories’ shares dropped 8% Thursday after the company provided disappointing forward guidance, despite solid second-quarter results. Revenue grew 7.4% to $11.14 billion, slightly exceeding estimates, and organic sales (excluding Covid tests) climbed 7.5%. Adjusted earnings per share rose 10.5% to $1.26, beating expectations.
The decline in stock can be attributed to Abbott’s unchanged full-year revenue guidance and slightly lower forecasts for Q3 earnings, raising investor concerns, especially regarding sluggish diagnostic sales in China and the potential impact of rival GLP-1 drugs on glucose monitoring sales.
Abbott reported strong performance in its medical device segment, with significant growth in diabetes care—particularly a 19.6% surge in glucose monitoring sales. Pharmaceutical sales also performed well, exceeding $1 billion in several emerging markets. However, the diagnostics segment saw an organic sales decline of 1.4%.
Concerning ongoing litigation about its formula for premature babies, Abbott maintains that there is no scientific evidence linking its product to reported health issues. CEO Robert Ford expressed commitment to regulatory compliance and emphasized the importance of medical professionals in treatment decisions.
Ultimately, despite Abbott’s strong product offerings and solid sales growth, the cautious guidance has led to a recommendation that investors should hold off on buying shares for now.
Source link
